Estring

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more

Treatment

5 FDA approvals

20 Active Studies for Estring

What is Estring

Estradiol

The Generic name of this drug

Treatment Summary

Estradiol is a hormone that is naturally found in women and is used to treat conditions caused by low estrogen levels, such as hot flashes and vaginal dryness. It comes in several forms, including tablets, injections, vaginal rings, patches, sprays, gels, and creams. Ethinyl estradiol is a synthetic form of estradiol that is commonly used in oral contraceptives. It is more effective when taken orally than estradiol because it has a higher bioavailability and is more resistant to being broken down in the body.

Estraderm

is the brand name

image of different drug pills on a surface

Estring Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Estraderm

Estradiol

1986

373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Hormonal Contraception and Breast Cancer .

Hormonal Contraception

Used to treat Hormonal Contraception therapy in combination with Levonorgestrel

Breast Cancer

Birth Control

Used to treat Contraception in combination with Levonorgestrel

Palliative Treatment

Breast Cancer

Effectiveness

How Estring Affects Patients

Estradiol is a hormone that helps to reduce hot flashes, vaginal dryness, and pain during sex. It can also increase bone density and have positive effects on the body's cholesterol levels. Estradiol can also increase certain proteins in the liver, such as sex hormone binding globulin and thyroid-binding globulin, and suppress the formation of follicle-stimulating hormone. However, it can also increase the risk of cardiovascular disease, deep vein thrombosis, and stroke, so it should be avoided in people at high risk for these conditions. Additionally, estradiol can cause a hyper-coagul

How Estring works in the body

Estrogen is found in many parts of the body and is produced mainly by the ovarian follicles in women who are still going through their reproductive period. After menopause, most estrogen is made by transforming androstenedione (from the adrenal cortex) to estrone. Estrogen works by binding to receptors in the body, including ERα and ERβ, which then enter the nucleus of the target cell and activate certain genes. This process causes the body to produce proteins that express the effects of estradiol. Estrogen has a range of effects, including reducing hot flashes, chills, mood swings, and sleep problems in

When to interrupt dosage

The encouraged measure of Estring is subject to the determined condition, for example, Premature Menopause, Pharmaceutical Preparations and Postmenopause. The amount of dosage is contingent on the technique of administration enumerated in the table beneath.

Condition

Dosage

Administration

Hot Flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Breast Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Vasomotor System

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

estradiol

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

female castration

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Therapeutic procedure

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Prostate Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Premature Menopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Pharmaceutical Preparations

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Palliative Treatment

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Breast

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Balanitis Xerotica Obliterans

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Hot flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Hormone Replacement Therapy

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Postmenopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Atrophic

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Amenorrhea

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Hypogonadism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Osteoporosis

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

hypoestrogenism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Warnings

Estring has eighteen contraindications. It should not be utilized in combination with the ailments presented in the following table.

Estring Contraindications

Condition

Risk Level

Notes

Breast

Do Not Combine

Angioedema

Do Not Combine

Venous Thrombosis

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Liver Dysfunction

Do Not Combine

Breast

Do Not Combine

suspected pregnancy

Do Not Combine

Breast Cancer

Do Not Combine

Pulmonary Embolism

Do Not Combine

Angioedema

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Thromboembolism

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Pulmonary Embolism

Do Not Combine

Thromboembolism

Do Not Combine

Thrombophilia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Estradiol may interact with Pulse Frequency

There are 20 known major drug interactions with Estring.

Common Estring Drug Interactions

Drug Name

Risk Level

Description

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Estradiol.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Estradiol.

Anastrozole

Major

The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Estradiol.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Estradiol.

Estring Toxicity & Overdose Risk

The amount of estradiol that is considered safe for rats to consume orally over a 90-day period is 0.003mg/kg/day. The highest dose of estradiol that has been found to be toxic to humans is 21mg/kg/21 days. Symptoms of estradiol overdose may include nausea, vomiting, abdominal pain, breast tenderness, blood clots, or vaginal bleeding. If an overdose occurs, it is recommended to cease using estradiol and provide supportive care.

Estring Novel Uses: Which Conditions Have a Clinical Trial Featuring Estring?

Currently, 867 clinical trials are assessing the potential of Estring to address Osteoporosis, Absent Menses for 6 Months or More and Urogenital Atrophy.

Condition

Clinical Trials

Trial Phases

Hysterectomy

4 Actively Recruiting

Phase 3, Not Applicable

Breast Cancer

19 Actively Recruiting

Phase 2, Phase 1, Not Applicable

estradiol

0 Actively Recruiting

Birth Control

19 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Postmenopause

4 Actively Recruiting

Phase 2, Not Applicable

Metastatic Breast Cancer

1 Actively Recruiting

Phase 1, Phase 2

Osteoporosis, Postmenopausal

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

moderate to severe symptoms

0 Actively Recruiting

Balanitis Xerotica Obliterans

0 Actively Recruiting

Amenorrhea

1 Actively Recruiting

Phase 2

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Prostate Cancer

71 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1

Breast

0 Actively Recruiting

Urogenital atrophy

0 Actively Recruiting

Low Testosterone

5 Actively Recruiting

Phase 4, Phase 2, Phase 1

Vasomotor System

0 Actively Recruiting

Atrophic Vaginitis

2 Actively Recruiting

Not Applicable, Phase 4

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3

Hormone Replacement Therapy

0 Actively Recruiting

Estring Reviews: What are patients saying about Estring?

5

Patient Review

5/5/2020

Estring for Vaginal Inflammation due to Loss of Hormone Stimulation

I've been using this for three months now and the only possible side effect is that my vision has gotten worse. I'm 59, so it might just be age. However, I can tell a difference in my vaginal tone and lubrication.

5

Patient Review

12/15/2020

Estring for Postmenopausal Urethral Atrophy

I bled for two days after sex, even though I had been using the vaginal cream for a year. But then I tried Estring and felt normal again within a month. The only downside is that now I can't afford it because I'm on Medicare. It's really sad that those who need it the most can't use the coupon.

5

Patient Review

5/20/2021

Estring for Postmenopausal Urethral Atrophy

Estring is great! Easy to use and comfortable. No mess! BUT don't waste your time until you know if your insurance covers it!

5

Patient Review

2/16/2022

Estring for Vaginal Inflammation due to Loss of Hormone Stimulation

I was so pleased with E String, and it worked perfectly for me for over two years. But then my consultant said I needed to take a break from it, and my GP couldn't tell me when or if I could use it again. Now my symptoms have returned and I'm using Vagirux instead, but I really want to go back on E String.

5

Patient Review

7/28/2022

Estring for Postmenopausal Urethral Atrophy

So far, I've been really pleased. It's easy to insert and there's no discomfort. I'm only a week in, but fingers crossed it will help with the pain and dryness I experience during sex.

4.7

Patient Review

5/24/2021

Estring for Postmenopausal Urethral Atrophy

I love this product, but I'm infuriated by how much more expensive it is for women than men's medication. It's not fair, and it puts a huge financial burden on already disadvantaged people.

4.3

Patient Review

4/6/2021

Estring for Postmenopausal Urethral Atrophy

The ring was a bit tough to remove, but I'm glad I stuck it out. It would have been helpful to know what the ideal feeling should be when removing the ring.

3.7

Patient Review

6/23/2020

Estring for Postmenopausal Urethral Atrophy

I love the Estring BUT why is its so hard to remove. I cannot do it by myself. Manufacturer should provide a device to remove it....I had a kind of "hook" to use when I had a diaphragm years ago.

3.3

Patient Review

11/15/2020

Estring for Postmenopausal Urethral Atrophy

The estring helped with my vaginal dryness and atrophy, as well as the pain I experienced during sex. However, there was a lot of discharge while using it. After eight months, I developed a bacterial infection which my doctor said was likely due to the estring. So, after finishing antibiotics, I'll be trying an estrogen cream instead.

3

Patient Review

9/13/2021

Estring for Postmenopausal Urethral Atrophy

I've used this for the past three years, but I can't seem to remove it on my own. My husband has to help me take it out. Additionally, I think it's caused me to gain weight around my middle.

1

Patient Review

2/26/2022

Estring for Postmenopausal Urethral Atrophy

I wasn't able to use this product because the ring is too large. Additionally, the contour makes it very difficult and uncomfortable to insert.

1

Patient Review

8/15/2022

Estring for Vaginal Inflammation due to Loss of Hormone Stimulation

The ring is very hard and big! I had a hard time getting it in and even worse trying to get it out. I used it for two weeks but got a bacterial infection so I stopped using it. The side effects weren't worth it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about estring

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the estring cause weight gain?

"Studies show that there is no link between estrogen and weight gain. The estrogen ring is not a factor in weight gain. Common factors that contribute to weight gain are age and lifestyle."

Answered by AI

What is estring used for?

"Estring is a soft, flexible ring used after menopause that continuously releases an estrogen over 3 months to treat menopausal changes in and around the vagina. It is important to keep in mind that estrogen therapies such as Estring should be used only as long as they are needed."

Answered by AI

Is estring considered HRT?

"There are two main types of HRT vaginal rings: Estring (estradiol) and Femring (estradiol acetate)."

Answered by AI

How long do you leave estring in?

"After 90 days of continued use, you and your doctor should talk about whether you still need treatment with Estring."

Answered by AI

Clinical Trials for Estring

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Waitlist Available
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Have you considered Estring clinical trials?

We made a collection of clinical trials featuring Estring, we think they might fit your search criteria.
Go to Trials
Image of University of Michigan Comprehensive Cancer Center in Ann Arbor, United States.

Self-Monitoring Platform for Cancer

18+
All Sexes
Ann Arbor, MI

This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.

Recruiting
Has No Placebo

University of Michigan Comprehensive Cancer Center

Yun Jiang

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Image of Mayo Clinic in Florida in Jacksonville, United States.

In-Home Treatment for Cancer

18+
All Sexes
Jacksonville, FL

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.

Phase 2
Recruiting

Mayo Clinic in Florida

Roxana S. Dronca, MD

Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Tabassum Ahmad, M.D.

Have you considered Estring clinical trials?

We made a collection of clinical trials featuring Estring, we think they might fit your search criteria.
Go to Trials
Image of Washington University School of Medicine in St Louis, United States.

Radium-223 for Prostate Cancer

18+
Male
St Louis, MO

Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \[223Ra\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development. Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Abhinav K Jha, Ph.D.

Image of City of Hope Medical Center in Duarte, United States.

Oral Cryotherapy for Prostate Cancer

18+
Male
Duarte, CA

This clinical trial studies whether cooling the mouth with popsicles (oral cryotherapy) decreases taste changes in prostate cancer patients receiving taxane chemotherapy. Patients receiving chemotherapy can experience a variety of side effects. Changes in the taste of food is a frequent complaint of patients receiving chemotherapy and is underreported as patients may think that it is unavoidable and not manageable. Taxane-based chemotherapy is thought to be associated with the most taste changes of any chemotherapy. Taste buds contain a specific type of cell, called gustatory cells, that are located on the surface of the tongue, the soft palate (back, muscular part of the roof of the mouth), and the upper part of the esophagus. These cells consist of five basic tastes: salty, sweet, sour, bitter, and umami (or savory). Oral cryotherapy involves cooling the mouth with ice chips, popsicles, or other cold drinks for several minutes before, during, and after chemotherapy causing the tiny blood vessels in the protective linings inside the mouth to narrow. It is thought that this narrowing will reduce blood flow to the cooled areas, thereby decreasing the amount of chemotherapy that is delivered to the fragile protective linings inside the mouth that causes the taste changes. This may be an effective way to decrease taste changes in prostate cancer patients receiving taxane chemotherapy.

Recruiting
Has No Placebo

City of Hope Medical Center

Jeannine M Brant

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Image of City of Hope Medical Center in Duarte, United States.

Metabolic Interventions for Prostate Cancer

30 - 79
Male
Duarte, CA

This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD) intervention on heart and blood vessel health (cardiovascular system) and how the body processes food for energy (metabolic system) in prostate cancer patients undergoing androgen deprivation therapy (ADT). Prostate cancer patients who are receiving hormonal therapy (ADT) are at an increased risk of cardiovascular disease. This is thought to be due to treatment-related metabolic changes which may result in increased weight, body fat, insulin resistance and an increased risk of heart attack, stroke or other heart and blood vessel problems. TRE (also known as intermittent fasting) is an eating plan that alternates between fasting and non-fasting periods. This approach limits calorie intake to a specific window of time each day. GLP1-RAs, semaglutide and tirzepatide are in a class of medications called incretin mimetics. They work by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. They also slow the movement of food through the stomach and may decrease appetite and cause weight loss. The AHA HHD guidelines may be an effective method to help people learn about following a heart healthy eating plan. This may lower their risk of cardiovascular disease. Metabolic interventions, TRE and GLP1-RA, may be more effective than an AHA HHD intervention alone in improving cardiovascular and metabolic health in prostate cancer patients undergoing ADT.

Phase 2
Recruiting

City of Hope Medical Center

Rose Li

Have you considered Estring clinical trials?

We made a collection of clinical trials featuring Estring, we think they might fit your search criteria.
Go to Trials